We are live on !
Find out more
TCG Crossover Management Portfolio holdings
AUM
$4.16B
Turnover
31.15%
1-Year Est. Return
983.43%
This Fund
S&P 500
This Quarter Est. Return
+18.76%
1 Year Est. Return
+983.43%
3 Year Est. Return
+3,012.95%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.18B
AUM Growth
+$221M
(+23%)
Cap. Flow
+$85.7M
Cap. Flow % of AUM
Cap. Flow %
7.26%
Top 10 Holdings %
Top 10 Hldgs %
58.4%
Holding
38
New
6
Increased
2
Reduced
5
Closed
2
Avg Time Held
1
year
Top 10 Avg Time Held
0.4
years
Top 20 Avg Time Held
1
year
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Xencor
XNCR
|
+$45.6M |
| 2 |
Fulcrum Therapeutics
FULC
|
+$38.9M |
| 3 |
Third Harmonic Bio
THRD
|
+$29.9M |
| 4 |
MBX Biosciences
MBX
|
+$14.9M |
| 5 |
Structure Therapeutics
GPCR
|
+$14.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Madrigal Pharmaceuticals
MDGL
|
+$41.8M |
| 2 |
Tarsus Pharmaceuticals
TARS
|
+$9.12M |
| 3 |
Mineralys Therapeutics
MLYS
|
+$8.65M |
| 4 |
C4 Therapeutics
CCCC
|
+$5.9M |
| 5 |
Silence Therapeutics
SLN
|
+$4.87M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
26
Entrada Therapeutics
TRDA
$170M
| $9.35M | 0.79% |
584,955
| – | – |
2021 Q4
11 quarters
|
|
27
VistaGen Therapeutics
VTGN
$8.88M
| $8.06M | 0.68% |
2,676,580
| – | – |
2023 Q4
3 quarters
|
|
|
28
Tarsus Pharmaceuticals
TARS
$3.19B
| $7.62M | 0.65% |
231,820
-324,497
| -58% | -$9.12M |
2023 Q3
4 quarters
|
|
29
EyePoint Inc
EYPT
$258M
| $7.37M | 0.62% |
922,335
| – | – |
2024 Q2
1 quarter
|
|
30
Nektar Therapeutics
NKTR
$1.22B
| $5.2M | 0.44% |
266,667
| – | – |
2024 Q1
2 quarters
|
|
31
Jade Biosciences
JBIO
$857M
| $4.68M | 0.4% |
64,023
| – | – |
2021 Q4
11 quarters
|
|
32
Avalo Therapeutics
AVTX
$604M
| $4.59M | 0.39% |
+483,000
| New | +$4.98M |
2024 Q3
0 quarters
|
|
33
Kodiak Sciences
KOD
$5.39B
| $2.63M | 0.22% |
1,008,158
+108,159
| +12% | +$288K |
2023 Q4
3 quarters
|
|
34
AN2 Therapeutics
ANTX
$128M
| $1.66M | 0.14% |
1,555,118
| – | – |
2023 Q2
5 quarters
|
|
35
DELISTED
Ventyx Biosciences
VTYX
| $689K | 0.06% |
316,195
| – | – |
2022 Q4
7 quarters
|
|
36
Cabaletta Bio
CABA
$239M
| $410K | 0.03% |
86,795
| – | – |
2022 Q4
7 quarters
|
|
|
37
C4 Therapeutics
CCCC
$341M
| – | – |
-1,276,574
| Closed | -$5.9M | – |
|
|
38
Madrigal Pharmaceuticals
MDGL
$10.4B
| – | – |
-149,283
| Closed | -$41.8M | – |
|
Similar funds
TCG Crossover Management's Q3 2024 Portfolio in Review
As of Q3 2024, TCG Crossover Management held 38 positions worth $1.18B, up 23% from $960M the previous quarter. Its ten largest holdings account for 58% of the portfolio.
TCG Crossover Management deployed $85.7M of net new capital in Q3 2024, opening 6 new positions and adding to 2 existing holdings. Its largest new stake was Xencor: 2,427,138 shares worth $48.8M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
On the sell side, the largest reduction was Tarsus Pharmaceuticals, an estimated $9.12M trimmed.
- TCG Crossover Management's largest Q3 2024 buy was Xencor: 2,427,138 shares worth $48.8M.
- TCG Crossover Management added most to Structure Therapeutics in Q3 2024, an estimated $14.2M increase.
- TCG Crossover Management's biggest Q3 2024 reduction was Tarsus Pharmaceuticals, cutting an estimated $9.12M.
- TCG Crossover Management fully exited Madrigal Pharmaceuticals in Q3 2024, selling an estimated $41.8M.
- TCG Crossover Management's ten largest holdings make up 58% of its $1.18B portfolio in Q3 2024.
- TCG Crossover Management opened 6 new positions and closed 2 in Q3 2024.
- TCG Crossover Management's portfolio value rose 23% quarter-over-quarter to $1.18B.
Based on TCG Crossover Management's 13F filing for Q3 2024, filed 14 Nov 2024.